10 Jun MDEA Finalist in IVD Product Category
AtomoRapid™ HIV has been selected as a finalist in the In Vitro Diagnostic Products and Systems Category at the 17th Medical Design Excellence Awards (MDEA), held in New York this week. The winners will be announced at an awards ceremony tomorrow night in New York.
The MDEA is the medtech industry’s premier design competition committed to searching worldwide for the highest caliber finished medical devices, products, systems, or packaging available on the market. The awards program celebrates the achievements of the medical device manufacturers, their suppliers, and the many people behind the scenes—engineers, scientists, designers, and clinicians—who are responsible for the cutting-edge products that are saving lives; improving patient healthcare; and transforming medtech—one innovation at a time
Atomo Diagnostics Founder & CEO John Kelly said: “Our company is delighted to be recognised for its work in developing AtomoRapid™, a revolutionary rapid diagnostic testing platform, and we would like to thank MDEA for selecting us as finalists in these prestigious awards, and our design partner, IDE for its excellent work in helping to bring this technology to market.
One of the 12 industry leader MDEA 214 judges George L. Walls, director of product and market development for ZOLL, said of AtomoRapid™:
“The AtomoRapid™ HIV hits on all cylinders: a real problem creatively and disruptively addressed. Fast, low cost, accurate, and fundamentally changing the use and business model in this important space. It’s EPT for HIV. ”